John A. Borgeson has sold KOD and made no open-market buys since Mar 2021

John A. Borgeson is the Executive Vice President and Chief Financial Officer of Kodiak Sciences Inc. (KOD), having joined the company in January 2016.( In this role, he oversees the company’s financial strategy, reporting, and operations and also serves as Secretary of Kodiak Sciences.( As a corporate insider, he has been a significant shareholder of Kodiak Sciences, holding over 180,000 shares of KOD.(

Borgeson has more than two decades of senior finance experience in the biopharmaceutical industry. Before joining Kodiak Sciences, he led finance functions for several private biotechnology companies between 2013 and 2015, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals.( Earlier in his career, he spent many years at Pfizer Inc. as a Vice President of Finance and member of Pfizer’s Global Finance and Business Operations Leadership Team, where his responsibilities included serving as finance head for Pfizer’s biotherapeutics and bioinnovation group and leading U.S. and European corporate tax functions.( Under his leadership, Pfizer executed a major restructuring of its global tax organization that became a model for other Fortune 50 companies.( Borgeson began his career as an auditor with Ernst & Young, is a certified public accountant (inactive), and holds an M.B.A. from the Rochester Institute of Technology and an undergraduate degree from the School of Management at the University at Buffalo (SUNY).(

Written by Perplexity from public sources.